deferoxamine has been researched along with Cerebral Infarction in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rat model of cerebral ischemia was established by middle cerebral artery occlusion with or without DFO administration." | 1.35 | Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. ( Ding, SJ; Guo, W; Li, YX; Xiao, L; Zhan, Q, 2008) |
| "Nimodipine was given at a dose of 1 mg/kg 1 hour before and 2 hours after the cold lesion." | 1.29 | Proposed toxic oxidant inhibitors fail to reduce brain edema. ( Bulkley, GB; Hedlund, BE; Judy, KD; Long, DM, 1994) |
| "The area of cerebral infarction was measured at three levels using video imaging methods." | 1.29 | Failure of iron chelators to protect against cerebral infarction in hypoxia-ischemia. ( Davis, J; Fridovich, I; MacMillan, V, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, SJ | 1 |
| Jeong, HJ | 1 |
| Moon, PD | 1 |
| Lee, KM | 1 |
| Moon, BS | 1 |
| Myung, NY | 1 |
| An, NH | 1 |
| Hong, SH | 1 |
| Um, JY | 1 |
| Kim, HM | 1 |
| Li, YX | 1 |
| Ding, SJ | 1 |
| Xiao, L | 1 |
| Guo, W | 1 |
| Zhan, Q | 1 |
| Judy, KD | 1 |
| Bulkley, GB | 1 |
| Hedlund, BE | 1 |
| Long, DM | 1 |
| MacMillan, V | 1 |
| Fridovich, I | 1 |
| Davis, J | 1 |
| Powars, DR | 1 |
| Wong, WY | 1 |
| Vachon, LA | 1 |
| Soloniuk, DS | 1 |
| Perkins, E | 1 |
| Wilson, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator[NCT00777140] | Phase 2 | 62 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for deferoxamine and Cerebral Infarction
| Article | Year |
|---|---|
Effect of Danchunwhangagam on LPS or DFX-induced cytokine production in peripheral mononuclear cells of cerebral infarction patients.
Topics: Aged; Cells, Cultured; Cerebral Infarction; Cytokines; Deferoxamine; Dose-Response Relationship, Dru | 2005 |
Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin.
Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Infarction; Deferoxamine; Disease Models, Animal; | 2008 |
Proposed toxic oxidant inhibitors fail to reduce brain edema.
Topics: Allopurinol; Animals; Brain Edema; Brain Injuries; Calcium; Cats; Cerebral Cortex; Cerebral Infarcti | 1994 |
Failure of iron chelators to protect against cerebral infarction in hypoxia-ischemia.
Topics: Animals; Brain; Brain Ischemia; Carbon Monoxide; Cerebral Infarction; Deferoxamine; Hypoxia, Brain; | 1993 |
Incomplete cerebral infarctions are not silent.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Bone Marrow Transplantation; Brain Damage, Chr | 2001 |
Use of allopurinol and deferoxamine in cellular protection during ischemia.
Topics: Allopurinol; Animals; Brain Ischemia; Cell Death; Cerebral Infarction; Deferoxamine; Rats | 1992 |